Cell-Seq™ — Scenic’s target discovery powerhouse
Our proprietary functional genomics engine, Cell-Seq™
Cell-Seq™, Scenic’s proprietary function-first genomics platform, enables the systematic identification of high-confidence therapeutic targets. Cell-Seq creates high-resolution disease maps that profile previously uncharted biological pathways and disease biology. This allows to uncover completely novel, potent drug targets that enable the development of first-in-class, disease-modifying therapies and form the basis for Scenic’s pipeline. We also leverage the power of Cell-Seq and its associated data warehouse in collaborations with pharma partners.
Innovative platform, grounded in strong science
Cell-Seq™ is disease-agnostic and has been broadly effective in finding new targets across therapeutic indications. Validated through 17 publications in leading journals including Nature and Science, Cell-Seq™ has attracted collaborations with global pharmaceutical leaders Genentech, Bristol Myers Squibb, Alnylam and Ono Pharmaceutical. Together, these partnerships reinforce the platform’s ability to uncover breakthrough biology and generate the next generation of first-in-class medicines.
With Cell-Seq, we are enabling the development of disease-modifying therapeutics for devastating diseases.
We are building the largest proprietary data warehouse of unchartered disease biology
We have identified novel drug targets for over a dozen diseases and built a robust pipeline of first-in-class small molecule inhibitors based on these targets. Discover our ongoing programs of discovery, development and collaborations!